Gilead Sciences and Arcellx have been collaborating on the a number of myeloma cell remedy anito-cel since 2022. This remedy was designed to offer higher security, which might be a bonus over Carvykti, the blockbuster a number of myeloma product marketed by Johnson & Johnson and Legend Biotech.
The put up Gilead Sciences Is Buying Arcellx and Partnered A number of Myeloma Drug in $7.8B Deal appeared first on MedCity Information.
